Release Details
Voyager Therapeutics Reports Third Quarter 2015 Financial Results
Initial public offering raised
Proof-of-concept data for lead clinical program, VY-AADC01, for Parkinson’s disease expected in second half of 2016
“2015 has been a transformative year for Voyager. We started the year by announcing a major strategic collaboration with Genzyme, followed by an oversubscribed series B financing, and recently completed a successful initial public offering. We also made significant progress on both our product pipeline and product engine, while continuing to expand our leadership team,” said
Recent Highlights and Upcoming Milestones
Corporate
- In
November 2015 , completed an initial public offering raising approximately$72.7 million in net proceeds. - Expanded the board of directors with the appointment of three industry and scientific leaders:
Perry Karsen , CEO of the Celgene Cellular Therapeutics division ofCelgene Corporation ;Michael Higgins , former COO and CFO ofIronwood Pharmaceuticals, Inc. and entrepreneur-in-residence atPolaris Partners ; andSteven Hyman , M.D., director of theStanley Center for Psychiatric Research at theBroad Institute of Harvard andMIT and a core faculty member of theBroad Institute . - Expanded the Voyager leadership team with the appointment of
John Connelly as vice president of program and alliance management andKathleen Hayes as vice president of human resources.
Product Pipeline and Product Engine
- Enrollment continued in the ongoing Phase 1b trial of VY-AADC01 for advanced Parkinson’s disease. In
October 2015 , reported encouraging interim clinical results and Voyager continues to expect to report top-line human proof-of-concept data in the second half of 2016. - In
October 2015 , the investigational new drug application (IND) for the ongoing Phase 1b trial of VY-AADC01 was transferred from theUniversity of California, San Francisco to Voyager. - Voyager’s four preclinical programs, VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich’s ataxia, VY-HTT01 for Huntington’s disease and VY-SMN101 for spinal muscular atrophy, all continued to advance, with Voyager’s next IND targeted for 2017.
- Continued advancement of the company’s product engine, including the areas of AAV vector engineering and optimization, manufacturing and dosing and delivery.
Third Quarter 2015 Financial Results
Cash, cash equivalents and marketable securities as of
For the quarter ended
- Research and development (R&D) expenses for the third quarter ended
September 30, 2015 , were approximately$6.5 million , compared to$2.4 million for the same period in 2014. The increase was largely due to expenditures in advancing development of Voyager’s pipeline and product engine, including increased R&D personnel costs associated with the growth of the company. - General and administrative (G&A) expenses were
$2.5 million for the quarter endedSeptember 30, 2015 , compared to$1.3 million for the same period in 2014. The increase was largely due to expenditures in G&A personnel associated with the growth of the company, and increased consulting and professional fees.
About
Forward-Looking Statements:
This press release contains forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical programs and clinical trials and our research and development programs, our ability to advance our AAV-based gene therapies into, and successfully complete, clinical trials, our ability to continue to develop our product engine, our ability to add new programs to our pipeline, and the timing or likelihood of regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in our final prospectus for our initial public offering filed with the
Selected Financial Information | |||||||||||||||||||||||||||||||||||
(amounts in thousands) | |||||||||||||||||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||||||||||||||||
Condensed Statement of Operations: | Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||||
September 30, | September 30, | ||||||||||||||||||||||||||||||||||
2015 |
2014 | 2015 | 2014 | ||||||||||||||||||||||||||||||||
Collaboration revenue | $ | 4,937 | $ | — | $ | 12,397 | $ | — | |||||||||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||||||||||||
Research and development | 6,481 | 2,399 | 18,459 | 5,938 | |||||||||||||||||||||||||||||||
General and administrative | 2,475 | 1,257 | 6,752 | 3,933 | |||||||||||||||||||||||||||||||
Total operating expenses | 8,956 | 3,656 | 25,211 | 9,871 | |||||||||||||||||||||||||||||||
Operating loss | (4,019 | ) | (3,656 | ) | (12,814 | ) | (9,871 | ) | |||||||||||||||||||||||||||
Other expense, net | |||||||||||||||||||||||||||||||||||
Interest income (expense), net | 102 | — | 175 | (2 | ) | ||||||||||||||||||||||||||||||
Other financing expense | — | (349 | ) | (9,750 | ) | (1,754 | ) | ||||||||||||||||||||||||||||
Total other expense, net | 102 | (349 | ) | (9,575 | ) | (1,756 | ) | ||||||||||||||||||||||||||||
Net loss | $ | (3,917 | ) | $ | (4,005 | ) | $ | (22,389 | ) | $ | (11,627 | ) |
Selected Balance Sheet Items: | September 30, | December 31, | ||||||||||
2015 | 2014 | |||||||||||
Cash, cash equivalents and marketable securities | $ | 160,593 | $ | 7,035 | ||||||||
Total assets | $ | 166,435 | $ | 11,497 | ||||||||
Accounts payable and accrued expenses | $ | 3,483 | $ | 2,196 | ||||||||
Deferred revenue | $ | 59,794 | $ | - | ||||||||
Redeemable convertible preferred stock | $ | 148,858 | $ | 21,979 | ||||||||
Total stockholders' deficit | $ | (47,139 | ) | $ | (20,830 | ) |
Contact: Investor Relations:Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah@sternir.com Media:Katie Engleman Pure Communications, Inc. 910-509-3977 Katie@purecommunicationsinc.com